Immunogenic Cell Death: Can It Be Exploited in PhotoDynamic Therapy for Cancer?
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Immunogenic Cell Death (ICD) could represent the keystone in cancer management since tumor cell death induction is crucial as well as the control of cancer cells revival after neoplastic treatment. In this context, the immune system plays a fundamental role. The concept of Damage-Associated Molecular Patterns (DAMPs) has been proposed to explain the immunogenic potential of stressed or dying/dead cells. ICD relies on DAMPs released by or exposed on dying cells. Once released, DAMPs are sensed by immune cells, in particular Dendritic Cells (DCs), acting as activators of Antigen-Presenting Cells (APCs), that in turn stimulate both innate and adaptive immunity. On the other hand, by exposing DAMPs, dying cancer cells change their surface composition, recently indicated as vital for the stimulation of the host immune system and the control of residual ill cells. It is well established that PhotoDynamic Therapy (PDT) for cancer treatment ignites the immune system to elicit a specific antitumor immunity, probably linked to its ability in inducing exposure/release of certain DAMPs, as recently suggested. In the present paper, we discuss the DAMPs associated with PDT and their role in the crossroad between cancer cell death and immunogenicity in PDT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002) · Nature · doi:10.1038/nature00858 · Cited by 4,221 · cited 2×
“e HMGB1 release as DAMP is widely demonstrated in necrotic cancer cells [139].”
BackgroundCalreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216 · cited 8×
“e dynamic exposure of CRT (ecto-CRT) on plasma membrane marks the cell for ICD [45].”
BackgroundInfluentialApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 2×
“It has been suggested that the physical interplay between TLR4 and HMGB1 [49] triggers an immunogenic signal operating downstream of the DCmediated antigen uptake that enables the optimal presentation of tumor antigens to T lymphocytes [73].”
BackgroundSterile inflammation: sensing and reacting to damage
Chen, G. Y., & Nuñez, G. (2010) · Nature Reviews Immunology · doi:10.1038/nri2873 · Cited by 3,051 · cited 1×
“On the other hand, TLR2 and TLR4, the most credited receptors for HSP60 and HSP70, respectively, are not strictly proin�ammatory [124].”
BackgroundGalluzzi, L., Vitale, I., Abrams, J. M., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., Dawson, T. M., Dawson, V. L., El-Deiry, W. S., Fulda, S., et al. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2011.96 · Cited by 2,421
Complement and its role in innate and adaptive immune responses
Dunkelberger, J. R., & Song, W.-C. (2010) · Cell Research · doi:10.1038/cr.2009.139 · Cited by 1,932 · cited 1×
“mediate response, playing a role in the adaptive immunity [191] carried out by antigen-speci�c B and T cells.”
BackgroundGhiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898 · cited 2×
“In effector phase, matured and activated DCs elicit an IFN-γγ-polarized T cell response, essential for efficient antitumor immunity [45, 49, 161].”
BackgroundFranchi, L., Eigenbrod, T., Muñoz-Planillo, R., & Nuñez, G. (2009) · Nature Immunology · doi:10.1038/ni.1703 · Cited by 1,834 · cited 6×
“ATP, released into the extracellular space during cellular stress, is the most abundant factor activating NLRP3 [162], that is essential for processing pro-IL-1𝛽𝛽 and secretion of IL1𝛽𝛽 [163], that, in turn, primes CD4+ and CD8+ lymphocytes and elicits the antitumor response.”
BackgroundInfluentialHow dying cells alert the immune system to danger
Kono, H., & Rock, K. L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2215 · Cited by 1,737
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., Park, D., Woodson, R. I., Ostankovich, M., Sharma, P., et al. (2009) · Nature · doi:10.1038/nature08296 · Cited by 1,654 · cited 1×
“ATP also functions as a ��nd me signal� promoting monocytes recruitment and activation [164].”
BackgroundCaspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Novel Signal Transduction Pathway Utilized by Extracellular HSP70
Asea, A., Rehli, M., Kabingu, E., Boch, J. A., Baré, O., Auron, P. E., Stevenson, M. A., & Calderwood, S. K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200497200 · Cited by 1,510
Gardai, S. J., McPhillips, K. A., Frasch, S. C., Janssen, W. J., Starefeldt, A., Murphy-Ullrich, J. E., Bratton, D. L., Oldenborg, P.-A., Michalak, M., & Henson, P. M. (2005) · Cell · doi:10.1016/j.cell.2005.08.032 · Cited by 1,473
Tian, J., Avalos, A. M., Mao, S.-Y., Chen, B., Senthil, K., Wu, H., Parroche, P., Drabic, S., Golenbock, D., Sirois, C., et al. (2007) · Nature Immunology · doi:10.1038/ni1457 · Cited by 1,372 · cited 1×
“Since nuclear DNA is released in a time-dependent manner following apoptosis induction [141] and since during apoptosis HMGB1-DNA binding increases, apoptotic cells can release DNA as well as HMGB1 during later stages, for example, secondary necrosis [130, 142, 143].”
BackgroundCancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324 · cited 1×
“, hyaluronan, heparin sulphate, and degraded matrix constituents) [59], and signals/structures not yet fully characterized, for example, tumor cell-derived exosomes [60, 61].”
BackgroundImmunogenic and tolerogenic cell death
Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2545 · Cited by 1,176 · cited 2×
“Recently, also apoptotic [41] and autophagic [140] cancer cells might release HMGB1 at some points in their respective execution phases.”
BackgroundmRNA is an endogenous ligand for toll-like receptor 3
Karikó, K., Ni, H., Capodici, J., Lamphier, M., & Weissman, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310175200 · Cited by 1,062 · cited 1×
“Plasma membrane collapse leads to release of (1) RNA molecules, interacting with TLR3 on DCs [51]; (2) double-stranded DNA, stimulating both macrophages and DCs [50]; (3) nucleotides, triggering maturation of DCs [147] through activation of the NFκκB signaling [151].”
BackgroundROS, mitochondria and the regulation of autophagy
Scherz-Shouval, R., & Elazar, Z. (2007) · Trends in Cell Biology · doi:10.1016/j.tcb.2007.07.009 · Cited by 954 · cited 1×
“Although autophagy is generally thought of as a cell survival strategy, the high reactivity of photogenerated ROS can commit tumor cells to their �nal demise [31].”
BackgroundMechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death
Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A., Chapman, D. C., Durchschlag, M., Joza, N., Pierron, G., van Endert, P., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.1 · Cited by 848 · cited 2×
“CRT translocation on plasma membrane occurs in a SNAREdependent exocytosis, based on a “CRT/Erp57 cotranslocation module” [71].”
BackgroundMethodA novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
Garg, A. D., Krysko, D. V., Verfaillie, T., Kaczmarek, A., Ferreira, G. B., Marysael, T., Rubio, N., Firczuk, M., Mathieu, C., Roebroek, A. J. M., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.497 · Cited by 800 · cited 10×
“Moreover, PDT-induced apoptotic cells have been predominantly associated with HSPs [204] and only recently it has been suggested the involvement of CRT andATP in apoptotic cell death upon photodynamic sensitization [70].”
BackgroundInfluentialKazama, H., Ricci, J.-E., Herndon, J. M., Hoppe, G., Green, D. R., & Ferguson, T. A. (2008) · Immunity · doi:10.1016/j.immuni.2008.05.013 · Cited by 627 · cited 3×
“�hen it is actively secreted by in�ammatory cells or passively released by necrotic cells [129], it acquires immunological potential based on its redox status [130] constituting a crucial step in the activation of APCs [49].”
BackgroundInside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox
Rubartelli, A., & Lotze, M. T. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.08.004 · Cited by 614 · cited 1×
“…October 2012 Academic Editor: Kristjan Plaetzer Copyright © 2013 Elisa Panzarini et al.is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.”
MethodDecoding Cell Death Signals in Inflammation and Immunity
Zitvogel, L., Kepp, O., & Kroemer, G. (2010) · Cell · doi:10.1016/j.cell.2010.02.015 · Cited by 558 · cited 1×
“e classical notion that apoptotic cell death is poorly immunogenic (or even tolerogenic), whereas necrotic cell death is truly immunogenic has been recently invalidated since it does not withstand experimental veri�cation, at least in models of tumor vaccination [11, 12].”
BackgroundThe extracellular release of HMGB1 during apoptotic cell death
Bell, C. W., Jiang, W., Reich, C. F., & Pisetsky, D. S. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00616.2005 · Cited by 538
HMGB1 release and redox regulates autophagy and apoptosis in cancer cells
Tang, D., Kang, R., Cheh, C.-W., Livesey, K. M., Liang, X., Schapiro, N. E., Benschop, R., Sparvero, L. J., Amoscato, A. A., Tracey, K. J., et al. (2010) · Oncogene · doi:10.1038/onc.2010.261 · Cited by 461 · cited 1×
“In particular, reducible HMGB1 decreases cell injury/death in cancer cells by interfering with Beclin 1, whereas oxidized HMGB1 enhances cell injury/death in response to anticancer agents [146].”
BackgroundSpisek, R., Charalambous, A., Mazumder, A., Vesole, D. H., Jagannath, S., & Dhodapkar, M. V. (2007) · Blood · doi:10.1182/blood-2006-10-054221 · Cited by 388 · cited 4×
“Once released, DAMPs are sensed by immune cells, in particular Dendritic Cells (DCs), acting as activators of Antigen-Presenting Cells (APCs), that in turn stimulate both innate and adaptive immunity.”
BackgroundInfluentialUric acid promotes an acute inflammatory response to sterile cell death in mice
Kono, H., Chen, C.-J., Ontiveros, F., & Rock, K. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40124 · Cited by 337 · cited 1×
“On the other hand, by exposing DAMPs, dying cancer cells change their surface composition, recently indicated as vital for the stimulation of the host immune system and the control of residual ill cells.”
BackgroundPhotodynamic therapy: illuminating the road from cell death towards anti-tumour immunity
Garg, A. D., Nowis, D., Golab, J., & Agostinis, P. (2010) · Apoptosis · doi:10.1007/s10495-010-0479-7 · Cited by 297 · cited 1×
“One recent therapeutic modality endowed with a known association with certain DAMPs is PhotoDynamic erapy (PDT), a Food and Drug Administration (FDA)-approved clinical protocol for the treatment of several malignant and nonmalignant diseases [15].”
BackgroundAutophagy regulates selective HMGB1 release in tumor cells that are destined to die
Thorburn, J., Horita, H., Redzic, J., Hansen, K., Frankel, A. E., & Thorburn, A. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.143 · Cited by 268 · cited 1×
“In the present paper, we discuss the DAMPs associated with PDT and their role in the crossroad between cancer cell death and immunogenicity in PDT.”
BackgroundEigenbrod, T., Park, J.-H., Harder, J., Iwakura, Y., & Núñez, G. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.12.8194 · Cited by 228 · cited 1×
“Particularly, cancer cells acquire six distinctive and complementary biological capabilities allowing tumor growth and metastatic dissemination. ese include self-sufficiency in growth signals, insensitivity to growth suppressors, circumventing cell death mechanisms, limitless replicative potential,…”
BackgroundPhotodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model
Castano, A. P., Mroz, P., Wu, M. X., & Hamblin, M. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709256105 · Cited by 201 · cited 1×
“Castano and collegues [202] observed that Tregs can be depleted by cyclophosphamide (CY) that, in combination with PBD-PDT, leads a long-term J774 reticulum cell sarcoma cure and resistance to tumor rechallenge.”
BackgroundPentraxins as a key component of innate immunity
Bottazzi, B., Garlanda, C., Salvatori, G., Jeannin, P., Manfredi, A., & Mantovani, A. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.11.009 · Cited by 168
Shiratsuchi, A., Watanabe, I., Takeuchi, O., Akira, S., & Nakanishi, Y. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2039 · Cited by 112
Culprits with evolutionary ties
Calfee, C. S., & Matthay, M. A. (2010) · Nature · doi:10.1038/464041a · Cited by 67
Cited by
Li, W., Yang, J., Luo, L., Jiang, M., Qin, B., Yin, H., Zhu, C., Yuan, X., Zhang, J., Luo, Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11269-8 · Cited by 1,120
Consensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
Self-citationThe emerging role of ferroptosis in inflammation
Sun, Y., Chen, P., Zhai, B., Zhang, M., Xiang, Y., Fang, J., Xu, S., Gao, Y., Chen, X., Sui, X., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110108 · Cited by 739
Solutions to the Drawbacks of Photothermal and Photodynamic Cancer Therapy
Deng, X., Shao, Z., & Zhao, Y. (2021) · Advanced Science · doi:10.1002/advs.202002504 · Cited by 590
Deng, G., Sun, Z., Li, S., Peng, X., Li, W., Zhou, L., Ma, Y., Gong, P., & Cai, L. (2018) · ACS Nano · doi:10.1021/acsnano.8b05292 · Cited by 416
Metadata
- Authors
- Panzarini, E., Inguscio, V., & Dini, L.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2013
- Volume
- 2013
- Pages
- 1-18
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W1992354862
- Cited by
- 114
- References
- 35
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.